Axios Pro Rata: Iambic intrigue

1. Key Themes

Theme: AI-for-drug-discovery valuations are splitting sharply between private and public markets

The Iambic vs. Isomorphic valuation gap

Iambic's IPO pricing is being measured against a private-market comp that is valued at roughly 40x its own price. Wall Street is trying to work out which side is mispriced.

• "Wall Street is scratching its head over Iambic Therapeutics, an AI biotech that plans to go public this week. Either it's the bargain of a lifetime or the private markets are wildly overvaluing one of its top comps, Alphabet-backed Isomorphic Labs."
• "Iambic would raise around $160 million at a $900 million valuation were it to price at the top of its IPO range, after having raised around $350 million from venture capital firms."
• "Last Thursday — the same day that Iambic launched its IPO roadshow — there was a Bloomberg report that Isomorphic 'is in early talks to raise new funds at a valuation of at least $40 billion.'"

Why the gap exists: brand premium, AI-first vs. bio-first, and public-market scar tissue

• "First, there seems to be a Google/Demis Hassabis premium on Isomorphic."
• "Second, Iambic's founding team is viewed as more bio-first, whereas Isomorphic's is viewed as more AI-first. And we all know which one investors currently value more."
• "Third, the public markets last year got burned by computational drug discovery setbacks at companies like Recursion and Schrödinger. Iambic would argue that it has an entirely different platform, and promising early data, but it must leapfrog memories that Isomorphic's private market investors don't share."

Iambic has clinical-stage substance Isomorphic lacks

• "It has a cancer candidate in early clinical trials with over 100 patients, and two more Phase 1 trials in the near-term pipeline."
• On Isomorphic: "It has not announced any clinical trials."
• Institutional validation: "Around $60 million of the IPO shares would be purchased by Stan Druckenmiller's Duquesne Family Office and existing investor Cathie Wood's ARK Investment Management."

Theme: Biotech IPO window is open but narrow, with pricing pressure

Biotech keeps filing, but pricing is the open question

• "Biotechs keep going public despite a narrowed IPO window, but pricing remains an open question."
• Evidence from the deal tables: TRex Bio "priced at the low end of its $14-$16 range"; City Therapeutics set terms "9.7m shares at $17-$19" for a "$1b fully diluted value at the midpoint"; Aspen Neuroscience and Bambusa Therapeutics filed for IPOs.
• Strategic investors are backing in: TRex Bio's backers include "Eli Lilly (which is buying back in via the IPO)."

Theme: Capital is concentrating in AI infrastructure and mega-rounds

Giant AI financings and acquisitions

• "TypeSafe AI (dba Jev), an SF-based composable AI startup led by OpenAI vet Diogo Almeida, raised around $870m at a $7.5b valuation. A16z led, joined by insiders DCVC and Sequoia Capital."
• "Oxide Computer, an Emeryville, Calif.-based on-premise cloud computing company, raised $445m in Series D funding."
• "Amazon (Nasdaq: AMZN) is in talks to buy Decart, a developer of world models and chip optimization software, for around $7b, per the WSJ."
• "SoftBank is in talks to raise a $100b fund focused on AI, per the FT."
• "Winverse AI, a Chinese developer of AI for robotics, is in talks to raise 'tens of millions of dollars' in seed funding at a $400m valuation led by DeepSeek, per Bloomberg."

Theme: Energy and "hard tech" continue to attract capital

Nuclear, thermal storage, and power infrastructure

• "Atlas Atomics, a nuclear startup cofounded by Vivek Ramaswamy, reportedly raised $400m at a $1.9b valuation. General Catalyst led, joined by a16z."
• "Epyr, a French industrial heat storage startup, raised €15m in Series A funding."
• "Base Electron, a power infrastructure company, said that it confidentially filed for an IPO."
• Counter-signal on data centers: "AirTrunk, an Australian data center operator owned by Blackstone and CPP Investment Board, is delaying a $1.5b REIT IPO until 2027."

2. Contrarian Perspectives

Perspective: The AI-drug-discovery bargain may be on the public side, not the private side The consensus assumes Isomorphic's $40B+ valuation is the "right" mark. The article frames the alternative: Iambic may simply be cheap, because investors are penalizing a bio-first team and discounting a platform with actual clinical data.

• "Either it's the bargain of a lifetime or the private markets are wildly overvaluing one of its top comps."
• Supporting evidence: Iambic has "a cancer candidate in early clinical trials with over 100 patients," while Isomorphic "has not announced any clinical trials," yet trades at an implied valuation more than 40x higher.
• The article's own explanation is reputational rather than fundamental: "a Google/Demis Hassabis premium" and the fact that "Isomorphic's private market investors don't share" the memory of public-market losses at Recursion and Schrödinger.

Perspective: A "decline" in the Getty-Shutterstock deal lets a distressed legacy asset become an AI-disruption turnaround for a patient owner Getty is framed as an AI casualty, yet sophisticated capital is putting in over half a billion dollars to own it.

• "Getty is the king of newswire photography, but its stock image business has been undercut by AI-generated images."
• "Koch and members of the Getty family will invest $533 million in equity, while lenders agreed to retire around $270 million of outstanding debt."
• The failed consolidation path: "Getty in June scrapped a $3.7 billion agreement to buy rival Shutterstock... after U.K. antitrust regulators insisted that Getty divest Shutterstock's editorial business."

3. Companies Identified

Iambic Therapeutics

• Description: AI biotech pursuing an IPO.
• Why mentioned: Central case study of the public/private AI-drug-discovery valuation disconnect.
• Quotes: "Iambic has developed a platform that it believes will be able to identify, develop and commercialize drugs using AI — a feat that thus far has been more dreamed than demonstrated." / "A source tells me that Iambic was floored by the Isomorphic report, and discussed whether or not to raise its target range."

Isomorphic Labs

• Description: Alphabet-backed AI drug discovery company led by Demis Hassabis.
• Why mentioned: Key private-market comp; reportedly raising at $40B+.
• Quotes: "Isomorphic 'is in early talks to raise new funds at a valuation of at least $40 billion.'"

Recursion and Schrödinger

• Description: Public computational drug discovery companies.
• Why mentioned: Their setbacks shape public-market skepticism of AI biotech.
• Quotes: "the public markets last year got burned by computational drug discovery setbacks at companies like Recursion and Schrödinger."

Getty Images

• Description: Photography/stock-image company being acquired by Koch Equity Development via prepackaged bankruptcy.
• Why mentioned: Case study of AI disruption of stock imagery and a failed M&A strategy.
• Quotes: "Getty is the king of newswire photography, but its stock image business has been undercut by AI-generated images." / "Three months later, its shares were delisted from the NYSE."

Koch Equity Development

• Description: Acquirer of Getty Images.
• Why mentioned: Providing the equity to take Getty private out of bankruptcy.
• Quotes: "Koch and members of the Getty family will invest $533 million in equity."

TypeSafe AI (Jev)

• Description: SF composable AI startup.
• Why mentioned: Largest VC round of the day.
• Quotes: "raised around $870m at a $7.5b valuation. A16z led."

Oxide Computer

• Description: On-premise cloud computing company.
• Why mentioned: $445M Series D with notable backers.
• Quotes: "Eclipse led, joined by US Innovative Technology Fund, Riot Ventures, Jane Street, Atreides Management, and AMD Ventures."

Atlas Atomics

• Description: Nuclear startup co-founded by Vivek Ramaswamy.
• Why mentioned: Large nuclear round.
• Quotes: "reportedly raised $400m at a $1.9b valuation. General Catalyst led, joined by a16z."

Decart

• Description: Developer of world models and chip optimization software.
• Why mentioned: Potential $7B Amazon acquisition.
• Quotes: "Decart previously held sale talks with Anthropic and has raised over $450m in VC funding."

IonQ / Elisity

• Description: Quantum computing company acquiring a network security firm.
• Why mentioned: Large stock acquisition.
• Quotes: "IonQ agreed to buy Elisity... for up to $1.3b in stock."

Starbucks / Chipotle

• Description: Restaurant companies in a rumored mega-merger.
• Why mentioned: Starbucks denied a takeover, moving both stocks.
• Quotes: "Starbucks yesterday said it has no plans to buy Chipotle, sending the coffee chain's stock up and the burrito business' stock down." / "which would have been the largest-ever restaurant sector merger."

Albertsons / Kroger

• Description: Grocers with a busted merger.
• Why mentioned: Litigation seeking damages.
• Quotes: "Albertsons is asking a Delaware court to force Kroger to pay more than $9b for their busted merger, arguing that Kroger didn't use its 'best efforts' to secure regulatory approval."

Roche / Rona Therapeutics

• Description: Big pharma licensing an obesity drug from a Chinese biotech.
• Why mentioned: Continued pharma sourcing from China.
• Quotes: "including $100m upfront and up to $1.06b in earnouts."

OPay

• Description: Africa-focused payments company.
• Why mentioned: Profitable fintech IPO filing.
• Quotes: "reports $91m of net income on $467m in revenue for the first half of 2026."

BlackRock / Humana

• Description: Joint venture for senior primary care clinics.
• Why mentioned: Large healthcare private-capital deal.
• Quotes: "to manage and operate nearly 150 CareWell Senior Primary Care clinics."

SoftBank

• Description: Investor reportedly raising an AI fund.
• Why mentioned: Scale of AI capital formation.
• Quotes: "is in talks to raise a $100b fund focused on AI, per the FT."

4. People Identified

Demis Hassabis

• Description: Google DeepMind co-founder; leads Isomorphic Labs.
• Why mentioned: His brand drives Isomorphic's valuation premium.
• Quotes: "Isomorphic, led by Google DeepMind co-founder Demis Hassabis." / "there seems to be a Google/Demis Hassabis premium on Isomorphic."

Stan Druckenmiller

• Description: Investor; Duquesne Family Office.
• Why mentioned: Anchor buyer in Iambic's IPO.
• Quotes: "Around $60 million of the IPO shares would be purchased by Stan Druckenmiller's Duquesne Family Office and existing investor Cathie Wood's ARK Investment Management."

Cathie Wood

• Description: ARK Investment Management founder.
• Why mentioned: Existing Iambic investor buying more in the IPO.
• Quotes: See above.

Frances Arnold

• Description: Nobel Prize winner; Alphabet board member; on Iambic's scientific advisory board.
• Why mentioned: Iambic's credibility counterweight to Isomorphic's Google halo.
• Quotes: "Even if Alphabet board member and Nobel Prize winner Frances Arnold is on Iambic's scientific advisory board."

Diogo Almeida

• Description: OpenAI veteran leading TypeSafe AI (Jev).
• Why mentioned: Led a $7.5B-valued startup.
• Quotes: "composable AI startup led by OpenAI vet Diogo Almeida."

Vivek Ramaswamy

• Description: Co-founder of Atlas Atomics.
• Why mentioned: Nuclear startup with $400M raise.
• Quotes: "a nuclear startup cofounded by Vivek Ramaswamy."

Mark Getty and Jonathan Klein

• Description: Founders of Getty Images.
• Why mentioned: Company history context.
• Quotes: "The company was founded in 1995 by Mark Getty, an heir to the Getty Oil fortune, and South African businessman Jonathan Klein."

Krishna Yeshwant

• Description: GV partner and co-head of life sciences.
• Why mentioned: Retiring from his partner role.
• Quotes: "is retiring as a partner and co-head of life sciences at GV, where he'll continue to serve as a managing partner emeritus."

5. Operating Insights

Know your comp set, because your private-market comps can reprice you overnight Iambic named Isomorphic as a competitor, and a single Bloomberg report on the same day as its roadshow launch forced a rethink of its own range.

• "Iambic was floored by the Isomorphic report, and discussed whether or not to raise its target range."

Pre-empt investor skepticism by explicitly differentiating from category failures Public investors anchor on prior failures in the category. The article notes Iambic must counter this with platform differentiation and early data.

• "Iambic would argue that it has an entirely different platform, and promising early data, but it must leapfrog memories that Isomorphic's private market investors don't share."

Anchor your IPO with credible, differentiated cornerstone investors A pre-arranged block from a marquee investor and an existing backer signals conviction and helps de-risk pricing.

• "Around $60 million of the IPO shares would be purchased by Stan Druckenmiller's Duquesne Family Office and existing investor Cathie Wood's ARK Investment Management."

6. Overlooked Insights

Regulatory risk can kill a consolidation strategy and force distress Getty's path from scrapped mega-deal to delisting to bankruptcy happened within months, a reminder that antitrust conditions can be fatal to a strategy dependent on scale.

• "Getty in June scrapped a $3.7 billion agreement to buy rival Shutterstock... after U.K. antitrust regulators insisted that Getty divest Shutterstock's editorial business. Getty then hired Guggenheim Securities to explore strategic alternatives. Three months later, its shares were delisted from the NYSE."

Chinese AI/biotech capital and assets are increasingly part of global dealmaking Roche is licensing from a Chinese biotech and DeepSeek is leading a seed round, suggesting Chinese ecosystems are both a source of assets and a capital provider.

• "Winverse AI, a Chinese developer of AI for robotics, is in talks to raise 'tens of millions of dollars' in seed funding at a $400m valuation led by DeepSeek, per Bloomberg."
• "Roche (SWX: ROP) signed an obesity drug licensing deal with VC-backed Chinese biotech Rona Therapeutics, including $100m upfront and up to $1.06b in earnouts."